Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Background and aims: Management of familial hypercholesterolaemia (FH) may vary across different settings due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey among the worldwide network of EAS FHSC Lead Investigators to provide an overview...

Full description

Bibliographic Details
Published in:Atherosclerosis
Main Author: Vallejo-Vaz A.J.; Marco M.D.; Stevens C.A.T.; Akram A.; Freiberger T.; Hovingh G.K.; Kastelein J.J.P.; Mata P.; Raal F.J.; Santos R.D.; Soran H.; Watts G.F.; Abifadel M.; Aguilar-Salinas C.A.; Al-Khnifsawi M.; Alkindi F.A.; Alnouri F.; Alonso R.; Al-Rasadi K.; Al-Sarraf A.; Ashavaid T.F.; Binder C.J.; Bogsrud M.P.; Bourbon M.; Bruckert E.; Chlebus K.; Corral P.; Descamps O.; Durst R.; Ezhov M.; Fras Z.; Genest J.; Groselj U.; Harada-Shiba M.; Kayikcioglu M.; Lalic K.; Lam C.S.P.; Latkovskis G.; Laufs U.; Liberopoulos E.; Lin J.; Maher V.; Majano N.; Marais A.D.; März W.; Mirrakhimov E.; Miserez A.R.; Mitchenko O.; Nawawi H.M.; Nordestgaard B.G.; Paragh G.; Petrulioniene Z.; Pojskic B.; Postadzhiyan A.; Reda A.; Reiner Ž.; Sadoh W.E.; Sahebkar A.; Shehab A.; Shek A.B.; Stoll M.; Su T.-C.; Subramaniam T.; Susekov A.V.; Symeonides P.; Tilney M.; Tomlinson B.; Truong T.-H.; Tselepis A.D.; Tybjærg-Hansen A.; Vázquez-Cárdenas A.; Viigimaa M.; Vohnout B.; Widén E.; Yamashita S.; Banach M.; Gaita D.; Jiang L.; Nilsson L.; Santos L.E.; Schunkert H.; Tokgözoğlu L.; Car J.; Catapano A.L.; Ray K.K.; Schreier L.; Pang J.; Dieplinger H.; Hanauer-Mader G.; Desutter J.; Langlois M.; Mertens A.; Rietzschel E.; Wallemacq C.; Isakovic D.; Dzankovic A.M.; Obralija J.; Pojskic L.; Sisic I.; Stimjanin E.; Torlak V.A.; Jannes C.E.; Krieger J.E.; Pereira A.C.; Ruel I.; Asenjo S.; Cuevas A.; Pećin I.; Miltiadous G.; Panayiotou A.G.; Vrablik M.; Benn M.; Heinsar S.; Béliard S.; Gouni-Berthold I.; Hengstenberg W.; Julius U.; Kassner U.; Klose G.; König C.; König W.; Otte B.; Parhofer K.; Schatz U.; Schmidt N.; Steinhagen-Thiessen E.; Vogt A.; Antza C.; Athyros V.; Bilianou E.; Boufidou A.; Chrousos G.; Elisaf M.; Garoufi A.; Katsiki N.; Kolovou G.; Kotsis V.; Rallidis L.; Rizos C.; Skalidis E.; Skoumas I.; Tziomalos K.; Shawney J.P.S.; Abbaszadegan M.R.; Aminzadeh M.; Hosseini S.; Mobini M.; Vakili R.; Zaeri H.; Agar R.; Boran G.; Colwell N.; Crowley V.; Durkin M.; Griffin D.; Kelly M.; Rakovac-Tisdall A.; Bitzur R.; Cohen H.; Eliav O.; Ellis A.; Gavish D.; Harats D.; Henkin Y.; Knobler H.; Leavit L.; Leitersdorf E.; Schurr D.; Shpitzen S.; Szalat A.; Arca M.; Averna M.; Bertolini S.; Calandra S.; Tarugi P.; Erglis A.; Gilis D.; Nesterovics G.; Saripo V.; Upena-Roze A.; Elbitar S.; Jambart S.; Khoury P.E.; Gargalskaite U.; Kutkiene S.; Al-Khateeb A.; An C.Y.; Ismail Z.; Kasim S.; Ibrahim K.S.; Radzi A.B.M.; Kasim N.A.; Nor N.S.M.; Ramli A.S.; Razak S.A.; Muid S.; Rosman A.; Sanusi A.R.; Razman A.Z.; Nazli S.A.; Kek T.L.; Azzopardi C.; Galán G.; Rubinstein A.; Magaña-Torres M.T.; Martagon A.; Mehta R.; Wittekoek M.E.; Isara A.R.; Obaseki D.E.; Ohenhen O.A.; Holven K.B.; Gruchała M.; Baranowska M.; Borowiec-Wolny J.; Gilis-Malinowska N.; Michalska-Grzonkowska A.; Pajkowski M.; Parczewska A.; Romanowska-Kocejko M.; Stróżyk A.; Żarczyńska-Buchowiecka M.; Kleinschmidt M.; Alves A.C.; Medeiros A.M.; Ershova A.; Korneva V.; Kuznetsova T.; Malyshev P.; Meshkov A.; Rozhkova T.; Popovic L.; Lukac S.S.; Stosic L.; Rasulic I.; Lalic N.M.; Chua T.S.J.; Ting S.P.L.; Raslova K.; Battelino T.; Cevc M.; Jug B.; Kovac J.; Podkrajsek K.T.; Sustar U.; Trontelj K.J.; Marais D.; Isla L.P.; Martin F.J.; Charng M.-J.; Chen P.-L.; Dell’oca N.; Fernández G.; Ressia A.; Reyes X.; Zelarayan M.; Alieva R.B.; Hoshimov S.U.; Nizamov U.I.; Kurbanov R.D.; Lima-Martínez M.M.; Nguyen M.-N.T.; Do D.-L.; Kim N.-T.; Le T.-T.; Le H.-A.
Format: Article
Language:English
Published: Elsevier Ireland Ltd 2018
Online Access:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85053666909&doi=10.1016%2fj.atherosclerosis.2018.08.051&partnerID=40&md5=09a021743fe130d0f3493e707aacd92c
Description
Summary:Background and aims: Management of familial hypercholesterolaemia (FH) may vary across different settings due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey among the worldwide network of EAS FHSC Lead Investigators to provide an overview of FH status in different countries. Methods: Lead Investigators from countries formally involved in the EAS FHSC by mid-May 2018 were invited to provide a brief report on FH status in their countries, including available information, programmes, initiatives, and management. Results: 63 countries provided reports. Data on FH prevalence are lacking in most countries. Where available, data tend to align with recent estimates, suggesting a higher frequency than that traditionally considered. Low rates of FH detection are reported across all regions. National registries and education programmes to improve FH awareness/knowledge are a recognised priority, but funding is often lacking. In most countries, diagnosis primarily relies on the Dutch Lipid Clinics Network criteria. Although available in many countries, genetic testing is not widely implemented (frequent cost issues). There are only a few national official government programmes for FH. Under-treatment is an issue. FH therapy is not universally reimbursed. PCSK9-inhibitors are available in ∼2/3 countries. Lipoprotein-apheresis is offered in ∼60% countries, although access is limited. Conclusions: FH is a recognised public health concern. Management varies widely across countries, with overall suboptimal identification and under-treatment. Efforts and initiatives to improve FH knowledge and management are underway, including development of national registries, but support, particularly from health authorities, and better funding are greatly needed. © 2018 Elsevier B.V.
ISSN:219150
DOI:10.1016/j.atherosclerosis.2018.08.051

Similar Items

  • Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration
    by: Vallejo-Vaz A.J.; Akram A.; Kondapally Seshasai S.R.; Cole D.; Watts G.F.; Hovingh G.K.; Kastelein J.J.P.; Mata P.; Raal F.J.; Santos R.D.; Soran H.; Freiberger T.; Abifadel M.; Aguilar-Salinas C.A.; Alnouri F.; Alonso R.; Al-Rasadi K.; Banach M.; Bogsrud M.P.; Bourbon M.; Bruckert E.; Car J.; Ceska R.; Corral P.; Descamps O.; Dieplinger H.; Do C.T.; Durst R.; Ezhov M.V.; Fras Z.; Gaita D.; Gaspar I.M.; Genest J.; Harada-Shiba M.; Jiang L.; Kayikcioglu M.; Lam C.S.P.; Latkovskis G.; Laufs U.; Liberopoulos E.; Lin J.; Lin N.; Maher V.; Majano N.; Marais A.D.; März W.; Mirrakhimov E.; Miserez A.R.; Mitchenko O.; Nawawi H.; Nilsson L.; Nordestgaard B.G.; Paragh G.; Petrulioniene Z.; Pojskic B.; Reiner Ž.; Sahebkar A.; Santos L.E.; Schunkert H.; Shehab A.; Slimane M.N.; Stoll M.; Su T.-C.; Susekov A.; Tilney M.; Tomlinson B.; Tselepis A.D.; Vohnout B.; Widén E.; Yamashita S.; Catapano A.L.; Ray K.K.
    Published: (2016)
  • Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial
    by: Connolly S.J.; Eikelboom J.W.; Bosch J.; Dagenais G.; Dyal L.; Lanas F.; Metsarinne K.; O'Donnell M.; Dans A.L.; Ha J.-W.; Parkhomenko A.N.; Avezum A.A.; Lonn E.; Lisheng L.; Torp-Pedersen C.; Widimsky P.; Maggioni A.P.; Felix C.; Keltai K.; Hori M.; Yusoff K.; Guzik T.J.; Bhatt D.L.; Branch K.R.H.; Cook Bruns N.; Berkowitz S.D.; Anand S.S.; Varigos J.D.; Fox K.A.A.; Yusuf S.; SALA J.; CARTASEGNA L.U.I.S.; VICO M.; HOMINAL M.A.; HASBANI E.; CACCAVO A.; ZAIDMAN C.; VOGEL D.; HRABAR A.; SCHYGIEL P.O.; CUNEO C.; LUQUEZ H.U.G.O.; MACKINNON I.J.; AHUAD GUERRERO R.A.; COSTABEL J.P.; BARTOLACCI I.P.; MONTANA O.; BARBIERI M.; GOMEZ VILAMAJO O.; GARCIA DURAN R.O.; SCHIAVI L.B.; GARRIDO M.; INGARAMO A.; BORDONAVA A.P.; PELAGAGGE M.J.; NOVARETTO L.; ALBISU DI GENNERO J.P.; IBANEZ SAGGIA L.M.; ALVAREZ M.; VITA N.A.; MACIN S.M.; DRAN R.D.; CARDONA M.; GUZMAN L.U.I.S.; SARJANOVICH R.J.; CUADRADO J.; NANI S.; LITVAK BRUNO M.R.; CHACON C.; MAFFEI L.E.; GRINFELD D.; VENSENTINI N.; MAJUL C.R.; LUCIARDI H.L.; GONZALEZ COLASO P.D.C.; FERRE PACORA F.A.; VAN DEN HEUVEL P.A.U.L.; VERHAMME P.; ECTOR B.A.V.O.; DEBONNAIRE P.; VAN DE BORNE P.; LEROY J.E.A.N.; SCHROE H.; VRANCKX P.; ELEGEERT I.V.A.N.; HOFFER E.; DUJARDIN K.A.R.L.; INDIO DO BRASIL C.; PRECOMA D.; ABRANTES J.A.; MANENTI E.; REIS G.; SARAIVA J.O.S.E.; MAIA L.; HERNANDES M.; ROSSI P.; ROSSI DOS SANTOS F.; ZIMMERMANN S.L.; RECH R.; ABIB E., et al.
    Published: (2018)
  • Sex Differences in Diagnosis, Treatment, and Cardiovascular Outcomes in Homozygous Familial Hypercholesterolemia
    by: Mulder J.W.C.M.; Tromp T.R.; Al-Khnifsawi M.; Blom D.J.; Chlebus K.; Cuchel M.; D'Erasmo L.; Gallo A.; Hovingh G.K.; Kim N.T.; Long J.; Raal F.J.; Schonck W.A.M.; Soran H.; Truong T.-H.; Boersma E.; Roeters van Lennep J.E.; Alareedh M.D.; Alieva R.; Allevi M.; Altunkeser B.B.; Al-Waili K.; Al-Zamili A.F.; Arca M.; Atzori L.; Averna M.; Ayesh M.H.; Azar S.T.; Banderali G.; Baratta F.; Bartuli A.; Béliard S.; Bianconi V.; Bini S.; Thani K.B.; Bitar F.F.; Blaha V.; Bonomo K.; Bourbon M.; Branchi A.; Brothers J.A.; Bruckert E.; Brunham L.R.; Bruzzi P.; Bucci M.; Buonuomo P.S.; Calabrò P.; Calandra S.; Carubbi F.; Cassiman D.; Casula M.; Catapano A.L.; Cavalot F.; Cefalù A.B.; Cesaro A.; Ceska R.; Charng M.-J.; Cipollone F.; Cohen H.; D'Addato S.; Dal Pino B.; Dann E.J.; Defesche J.C.; Del Ben M.; Demircioglu S.; Descamps O.S.; Di Costanzo A.; Di Taranto M.D.; Do D.-L.; Durst R.; Dvorakova J.; Ebenbichler C.F.; Elis A.; Emil S.; Ezhov M.V.; Fahed A.C.; Fasano T.; Ferri C.; Fogacci F.; Formisano E.; Fortunato G.; Francis G.A.; Freiberger T.; Galimberti F.; Gaspar I.M.; Genest J.; Gentile M.; Giammanco A.; Gokce C.; Greber-Platzer S.; Grigore L.; Groselj U.; Harada-Shiba M.; Hartgers M.L.; Hegele R.A.; Horak P.; Hori M.; Hudgins L.C.; Hussein O.; Iannuzzo G.; Ilhan O.; Iughetti L.; Kayikcioglu M.; Kaynar L.G.; Kennedy B.A.; Khovidhunkit W.; Kolovou G.; Kose M.; Kuku I.; Kurtoglu E.; Lalic K.S.; Le H.-A.; Le T.-T.; Leitersdorf E.; Liberopoulos E.; Lyons A.R.M.; Madriz R.; Mandraffino G.; Mäser M.; Mehta R.; Mitchenko O.; Mombelli G.; Montalcini T.; Morace C.; Moubarak E.M.; Muntoni S.; Naguib T.A.; Nascimbeni F.; Nawawi H.; Nemer G.; Nguyen M.-N.T.; Notargiacomo S.; Okutan H.; Ozcebe O.I.; Pang J.; Passaro A.; Pavanello C.; Pecchioli L.; Pecchioli V.; Pederiva C.; Pekkolay Z.; Pellegatta F.; Piro S.; Pirro M.; Pisciotta L.; Pujia A.; Ray K.K.; Reda A.; Reijman M.D.; Reiner Ž.; Rhadi S.H.; Rizzi L.; Romandini A.; Ruel I.; Rymen D.; Sadiq F.; Sag S.; Salcioglu O.Z.; Santos R.D.; Sanz J.M.; Sarzani R.; Sbrana F.; Schurr D.; Scicali R.; Setia N.; Shaghee F.K.; Shek A.; Sherman M.H.; Soska V.; Stevens C.A.T.; Stroes E.S.G.; Stulnig T.M.; Suppressa P.; Susekov A.V.; Tarugi P.; Temizhan A.; Tichy L.; Trenti C.; Urbanek R.; Vallejo-Vaz A.J.; Vaverkova H.; Verma I.C.; Vrablik M.; Wang L.; Watts G.F.; Werba J.P.; Wiegman A.; Witters P.; Yenercag M.; Yilmaz M.; Yasar H.Y.; Zambon A.; Zambon S.; Zemek S.; Zenti M.G.; Zlatohlavek L.; Zuurbier L.
    Published: (2024)
  • Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial
    by: Bosch J.; Eikelboom J.W.; Connolly S.J.; Bruns N.C.; Lanius V.; Yuan F.; Misselwitz F.; Chen E.; Diaz R.; Alings M.; Lonn E.M.; Widimsky P.; Hori M.; Avezum A.; Piegas L.S.; Bhatt D.L.; Branch K.R.H.; Probstfield J.L.; Liang Y.; Liu L.; Zhu J.; Maggioni A.P.; Lopez-Jaramillo P.; O'Donnell M.; Fox K.A.A.; Kakkar A.; Parkhomenko A.N.; Ertl G.; Störk S.; Keltai K.; Keltai M.; Ryden L.; Dagenais G.R.; Pogosova N.; Dans A.L.; Lanas F.; Commerford P.J.; Torp-Pedersen C.; Guzik T.J.; Verhamme P.B.; Vinereanu D.; Kim J.-H.; Ha J.-W.; Tonkin A.M.; Varigos J.D.; Lewis B.S.; Felix C.; Yusoff K.; Steg P.G.; Aboyans V.; Metsarinne K.P.; Anand S.S.; Hart R.G.; Lamy A.; Moayyedi P.; Leong D.P.; Sharma M.; Yusuf S.
    Published: (2017)
  • Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin
    by: Moayyedi P.; Eikelboom J.W.; Bosch J.; Connolly S.J.; Dyal L.; Shestakovska O.; Leong D.; Anand S.S.; Störk S.; Branch K.R.H.; Bhatt D.L.; Verhamme P.B.; O'Donnell M.; Maggioni A.P.; Lonn E.M.; Piegas L.S.; Ertl G.; Keltai M.; Bruns N.C.; Muehlhofer E.; Dagenais G.R.; Kim J.-H.; Hori M.; Steg P.G.; Hart R.G.; Diaz R.; Alings M.; Widimsky P.; Avezum A.; Probstfield J.; Zhu J.; Liang Y.; Lopez-Jaramillo P.; Kakkar A.K.; Parkhomenko A.N.; Ryden L.; Pogosova N.; Dans A.L.; Lanas F.; Commerford P.J.; Torp-Pedersen C.; Guzik T.J.; Vinereanu D.; Tonkin A.M.; Lewis B.S.; Felix C.; Yusoff K.; Metsarinne K.P.; Fox K.A.A.; Yusuf S.
    Published: (2019)